According to the Zhixun finance APP, Mingke Pharmaceutical (688373.SH) released its semi-annual report for 2024. During the reporting period, the company achieved a revenue of 60.7382 million yuan, a year-on-year increase of 44.24%. The net loss attributable to shareholders of the listed company was 0.201 billion yuan. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 0.212 billion yuan. The basic loss per share was 0.31 yuan.